Common name
N-methylacetamide
IUPAC name
N-methylacetamide
SMILES
N(C(=O)C)C
Common name
N-methylacetamide
IUPAC name
N-methylacetamide
SMILES
N(C(=O)C)C
INCHI
InChI=1S/C3H7NO/c1-3(5)4-2/h1-2H3,(H,4,5)
FORMULA
C3H7NO
Common name
N-methylacetamide
IUPAC name
N-methylacetamide
Molecular weight
73.094
clogP
-0.391
clogS
-0.518
Frequency
0.0175
HBond Acceptor
1
HBond Donor
1
Total PolarSurface Area
29.1
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00006 | Felypressin |
|
Vasoconstrictor Agents; Renal Agents; | For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential. |
| FDBD00034 | Glutathione |
|
Antidotes; Dietary Supplements; Micronutrients; Supplements; | For nutritional supplementation, also for treating dietary shortage or imbalance. |
| FDBD00066 | Valsartan |
|
Antihypertensive Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Lipid Modifying Agents; Cardiovascular System; Angiotensin II Antagonists, Plain; Agents Acting on the Renin-Angiotensin System; Angiotensin II Antagonists and Diuretics; Angiotensin II Antagonists and Calcium Channel Blockers; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Angiotensin II Receptor Antagonists; | May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors. |
| FDBD00077 | Bortezomib |
|
Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies. |
| FDBD00100 | Remikiren |
|
Cardiovascular System; Agents Acting on the Renin-Angiotensin System; Renin-Inhibitors; | For the treatment of hypertension and heart failure. |
| FDBD00113 | Gadodiamide |
|
Contrast Media; Paramagnetic Contrast Media; Magnetic Resonance Imaging Contrast Media; | For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues. |
| FDBD00200 | Capreomycin |
|
Anti-Bacterial Agents; Protein Synthesis Inhibitors; Antibiotics, Antitubercular; Antibiotics; Antimycobacterials; Antiinfectives for Systemic Use; Drugs for Treatment of Tuberculosis; | Used in the treatment of tuberculosis in combination with other drugs. |
| FDBD00376 | Ritonavir |
|
Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); CYP3A4 Inhibitors; Combined Inducers of CYP3A4 and P-glycoprotein; Combined Inhibitors of CYP3A4 and P-glycoprotein; | Indicated in combination with other antiretroviral agents for the treatment of HIV-infection. |
| FDBD00405 | Gadoversetamide |
|
Contrast Media; Paramagnetic Contrast Media; Magnetic Resonance Imaging Contrast Media; | Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors. |
| FDBD00466 | Linezolid |
|
Anti-Bacterial Agents; Protein Synthesis Inhibitors; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; | For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant . |
51 ,
6
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1oth_ligand_2_12.mol2 | 1oth | 1 | -6.03 | CNC(=O)C | 5 |
| 2h3e_ligand_2_4.mol2 | 2h3e | 1 | -6.02 | C(=O)(NC)C | 5 |
| 1a7c_ligand_2_82.mol2 | 1a7c | 1 | -5.96 | CNC(=O)C | 5 |
| 2g1r_ligand_1_4.mol2 | 2g1r | 1 | -5.95 | CNC(=O)C | 5 |
| 5abe_ligand_1_0.mol2 | 5abe | 1 | -5.95 | CC(=O)NC | 5 |
| 5abh_ligand_1_6.mol2 | 5abh | 1 | -5.95 | CC(=O)NC | 5 |
| 1a7c_ligand_1_0.mol2 | 1a7c | 1 | -5.91 | N(C(=O)C)C | 5 |
| 1css_ligand_2_165.mol2 | 1css | 1 | -5.91 | CC(=O)NC | 5 |
1405 ,
141
